Screener
Royalty Pharma RPRX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net income attributable to non-controlling interests | 63,603 | 60,459 | 237,169 | 255,543 |
| Net income attributable to Royalty Pharma plc | $17,883 | $32,176 | $312,572 | $271,525 |
| Earnings per Class A ordinary share: | ||||
| Basic | $0.04 | $0.08 | $0.71 | $0.63 |
| Diluted | $0.04 | $0.07 | $0.71 | $0.63 |
| Weighted average Class A ordinary shares outstanding: | ||||
| Basic | 445,064 | 423,514 | 440,950 | 429,464 |
| Diluted | 556,896 | 562,298 | 557,352 | 570,157 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's EPS (diluted)?
- Royalty Pharma (RPRX) reported EPS (diluted) of $0.04 in Q2 2026.
- How has Royalty Pharma's EPS (diluted) changed year-over-year?
- Royalty Pharma's EPS (diluted) decreased by 42.9% year-over-year, from $0.07 to $0.04.
- What is the long-term trend for Royalty Pharma's EPS (diluted)?
- Over 3 years (2021 to 2025), Royalty Pharma's EPS (diluted) has grown at a 6.1% compound annual growth rate (CAGR), from $1.50 to $1.79.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Royalty Pharma's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude